

V Pre Congress Meeting SEHH-DANA FARBER 2016



From stem cell to the treatment of hematological disease

Venue

Palacio de Congresos y Exposiciones de Galicia

Rúa de Miguel Ferro Caaveiro

15707 Santiago de Compostela

Co-Chairman:

Dr. José Luis Bello

Complejo Hospitalario
Universitario de Santiago
de Compostela

Co-Chairman:

Dr. Irene Ghobrial

Dana-Farber Cancer Institute,
Boston

Organized by



Under the auspices of:



Thanks to an unrestricted grant of:



11:00-11:10 h

Welcome

Dr. José Luis Bello. Complejo Hospitalario Universitario de Santiago de Compostela
Dr. Irene Ghobrial. Dana-Farber Cancer Institute. Boston

11:10-11:30 h

Immuno-oncology: from clonality to malignancy

Dr. Alberto Orfao. Hospital Universitario de Salamanca

MYELODYSPLASTIC SYNDROME/MYELOID ACUTE LEUKEMIA

Chair: Dr. Jordi Esteve. Hospital Clínic. Barcelona

11:30-11:40 h

Immunophenotype of CD34+ precursor and stem cells

Dr. Alberto Orfao. Hospital Universitario de Salamanca

11:40-12:00 h

Cytogenetic and genetic findings in MDS

Dr. Francesc Solé. Fundació Josep Carreras contra la Leucemia. Barcelona

12:00-12:15 h

How & when we treat low risk MDS?

Dr. María D. Campelo. Hospital Universitario de Salamanca

12:15-12:30 h

Treatment options for MDS patients beyond hypomethylant treatment

Dr. Antonio Almeida. Instituto Português de Oncologia. Lisboa

12:30-12:40 h

Myeloid differentiation

Dr. Alberto Orfao. Hospital Universitario de Salamanca

12:40-13:00 h

Targeting treatment in AML patient

Dr. Daniel de Angelo. Dana-Farber Cancer Institute. Boston

13:00-13:20 h

Measuring survival and response in elderly AML patients

Dr. Fernando Ramos. Complejo Asistencial Universitario de León

13:20-13:30 h

Panel discussion

13:30-14:30 h

Lunch

NON-HODGKIN LYMPHOMA

Chair: Dr. Miguel Canales. Hospital Universitario La Paz. Madrid

14:30-14:40 h

Lymphoid maturation: from CD34+ precursors to lymphocytes

Dr. Alberto Orfao. Hospital Universitario de Salamanca

14:40-15:05 h

Diagnosis and clinicopathological variants of MCL: implications for treatment

Dr. Pedro Jares. Hospital Clínic. Barcelona

15:05-15:30 h

DLBCL: new insights in molecular subtyping and next treatment paradigm

Dr. Maria G. da Silva. Instituto Português de Oncologia. Lisboa

15:30-15:55 h

Risk of transformation of FL and treatment outcomes

Dr. Armando L. Guillermo. Hospital Clínic. Barcelona

15:55-16:20 h

Immuno-oncological therapies: a new approach in lymphoma

Dr. Matthew S. Davids. Dana-Farber Cancer Institute. Boston

16:20-16:30 h

Panel discussion

16:30-17:00 h

Coffee break

MULTIPLE MYELOMA

Chair: Dr. Irene Ghobrial. Dana-Farber Cancer Institute. Boston

17:00-17:10 h

Antigen-driven B-cell maturation: from B-lymphocytes to plasma cells

Dr. Alberto Orfao. Hospital Universitario de Salamanca

17:10-17:30 h

Minimal residual clone or minimal residual disease?

Dr. Bruno Paiva. Clínica Universidad de Navarra. Pamplona

17:30-17:50 h

Immunotherapies: a new paradigm in the MM approach

Dr. Aldo Roccaro. Dana-Farber Cancer Institute. Boston

17:50-18:10 h

Synergistic mechanism of action between new drug combinations in MM: a step forward in immunomodulation

Dr. Irene Ghobrial. Dana-Farber Cancer Institute. Boston

18:10-18:30 h

What have we learnt about combination therapies in MMRR?

Dr. Paulo Lucio. Fundação Champalimaud. Lisboa

18:30-18:50 h

How close we are to cure MM?

Dr. Jesús F. San Miguel. Clínica Universidad de Navarra. Pamplona

18:50-19:00 h

Panel discussion

19:00-19:15 h

Summary and take home messages

Dr. José Luis Bello. Complejo Hospitalario Universitario de Santiago de Compostela

V Pre Congress Meeting SEHH-DANA FARBER 2016

From stem cell to the treatment of hematological disease

